Exact Sciences

Exact argues that JHU has no basis to demand any royalties on sales of Cologuard because the test doesn't use any patents the university licensed to the company.

News items for the week of Nov. 4, 2019.

The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.

After the merger closes, the combined company will be split into four units focused on Cologuard, Oncotype Dx, international business, and pipeline efforts.

The Voyage study is designed to enroll more than 150,000 people and will follow participants for at least seven years.

The FDA gave the nod to Shenzhen Bioeasy Biotechnology for two lateral flow immunoassays that provide preliminary results in detecting marijuana in urine. 

Of the 29 companies in the index, 16 firms' share prices retreated while the other 13 saw their stock prices rise month over month.

The agency has approved the use of Exact's Cologuard test for average-risk individuals aged 45 and older.

The study said that Cologuard was an "inefficient screening option" for colorectal cancer given its cost as compared to other CRC screening methods.